Dr. Elizabeth M. Gaughan, MD

Dr. Gaughan practices at Emily Couric Clinical Cancer Center in Charlottesville, Virginia.

Dr. Gaughan's NPI, 1780842872, was assigned on May 27, 2008. Dr. Gaughan graduated from Georgetown University School of Medicine in 2006. Dr. Gaughan holds Virginia license 0101251915.

Dr. Gaughan's primary practice is Emily Couric Clinical Cancer Center, at 1240 Lee St,, Charlottesville, VA 22903. The practice phone is (434) 243-4704.

Dr. Gaughan's primary practice is Emily Couric Clinical Cancer Center in Charlottesville, Virginia. Dr. Gaughan is also affiliated with University Medical Center. The medical group on file is UVA Physicians Group. Dmand AI also links Dr. Gaughan to 4 more hospitals and 1 group practice or clinic, each named with a free account. Dr. Gaughan's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gaughan practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Gaughan's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Gaughan's licenses on file in 2 states: Virginia and Massachusetts.

CMS data shows 854 Medicare services from Dr. Gaughan across 5 procedure codes in 2024, for 258 Medicare patients. Medicare paid $56,821 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 258 Medicare patients who saw Dr. Gaughan in 2024. The largest group is 65 to 74, with 104 patients. 71% of them have high blood pressure, and 71% have high cholesterol. 5% are also on Medicaid. Their average risk score is 2.33, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gaughan's median patient age at 68, with 41% women.

In 2024, Dr. Gaughan wrote 117 Medicare Part D claims for 37 patients. 62% of them were for generic drugs. CMS names the drug for 59 of them, across 4 drugs with 11 or more claims each, at $207,842 in total drug cost. In 2023, CMS named 57 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Gaughan for performance year 2024, reported as part of a group. Dr. Gaughan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gaughan as offering telehealth.

Dmand AI links 27 papers to Dr. Gaughan, published from 2011 to 2024. 2022 was the busiest year, with 3. The most frequent topics are Melanoma, Cancer Vaccines and CD4-Positive T-Lymphocytes. Dr. Gaughan has published most often in J Immunother Cancer. Dr. Gaughan's most frequent co-authors are Craig L. Slingluff, MD, Ryan D. Gentzler, MD and Kelly Smith, MD.

Dmand AI links Dr. Gaughan to 7 clinical trials, 3 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Lymphoid Interstitial Pneumonia. National Cancer Institute (NCI) sponsors the most, 5. Open Payments lists research payments to Dr. Gaughan that name 1 trial.

CMS Open Payments shows 14 general payments to Dr. Gaughan from 5 drug and device companies from 2016 to 2024. Travel and lodging make up the largest share, 59% of the total. Novartis Pharmaceuticals Corporation paid the most, $1,245. It also lists 9 research payments totaling $1,692 in 2023, naming 1 clinical trial.

Dr. Gaughan graduated from Georgetown University School of Medicine in 2006.